Published on 01/12/2025

Sampling Strategies: Stratified, Time-Based, and Risk-Based

Understanding AI/ML Model Validation in GxP Analytics

The pharmaceutical industry is increasingly leveraging Artificial Intelligence (AI) and Machine Learning (ML) technologies to enhance drug development, improve operational efficiencies, and ensure compliance with regulatory standards. However, the validation of AI/ML models, particularly in a Good Practice (GxP) context, requires meticulous attention to intended use and data readiness. This article serves as a step-by-step tutorial on different sampling strategies—stratified, time-based, and risk-based—necessary for effective AI/ML model validation.

With regulations such as 21 CFR Part 11 in the US, and EMA guidelines in the EU, companies must ensure that their AI/ML systems comply with standards governing security, traceability, and validation. This article will guide professionals through the necessary steps for implementing these sampling strategies, alongside considerations for bias and fairness testing, model verification and validation, and maintaining an audit trail.

Step 1: Defining the Intended Use of AI/ML Models

Before engaging with specific sampling strategies, it is critical to establish the intended use of the AI/ML model. “Intended use” refers to the purpose the model is designed to accomplish, which can significantly affect the data gathering and sampling strategy. Clearly defining this will streamline the validation process and satisfy regulatory requirements.

For instance, if the model is developed for patient stratification in clinical trials, ensuring that the input data mirrors the demographics of the intended patient population becomes pivotal. To facilitate this step:

• Identify Objectives: Outline what outcomes the model is expected to predict or assist with.
• User Personas: Define the end users of the model, including clinical and operational stakeholders.
• Regulatory Expectations: Review relevant guidelines that dictate how intended use should be articulated, referencing documents from ICH and local governing bodies.

Step 2: Ensuring Data Readiness and Curation

Data readiness is vital for the success of AI/ML projects. This step encompasses the collection, preparation, and validation of data, ensuring it meets necessary quality standards. It is crucial to curate datasets that not only match your model’s intended use but also minimize biases that may lead to unfair outcomes.

The process of curating data can be broken into manageable steps:

• Data Collection: Gather data from a variety of sources to ensure representativeness. This may involve clinical data, electronic health records, and historical trial data.
• Cleaning and Preprocessing: Ensure data is devoid of inaccuracies, duplications, or irrelevant entries, which include addressing missing values and standardizing formats.
• Bias and Fairness Testing: Assess the dataset for inherent biases. Employ strategies such as stratified sampling to ensure equitable representation of various demographic groups.

Thorough documentation through audit trails during this process is essential for regulatory compliance, and consultations should reference GAMP 5 standards.

Step 3: Sampling Strategies for Model Validation

Effective sampling strategies are necessary to validate the AI/ML models comprehensively. The choice of strategy impacts the validity of the resulting insights and the subsequent decision-making processes. Three primary sampling strategies are commonly applied:

Stratified Sampling

Stratified sampling involves dividing the population into distinct strata or groups, ensuring that all relevant subgroups are represented within the sample. This method is particularly useful for addressing the intended use of the model and enhancing its fairness and accuracy. Here’s how to apply stratified sampling:

• Define Stratification Criteria: Establish key attributes based on demographic, clinical, or biological characteristics relative to the intended use.
• Sample Selection: Randomly select samples from each stratum to ensure proportional representation.
• Data Analysis: Validate the model across each stratum to assess performance consistency and reliability.

Time-Based Sampling

Time-based sampling focuses on collecting samples at specific time intervals or events to capture temporal patterns in data that might influence model output. This method is particularly relevant in contexts where changes over time might significantly affect predictions, such as in patient monitoring scenarios. The steps include:

• Select Time Intervals: Determine the baseline and subsequent time points for data collection.
• Monitor Data Trends: Analyze how data characteristics change over time and ensure they align with model predictions.
• Periodical Re-evaluation: Conduct periodic reviews to validate and recalibrate the model as necessary.

Risk-Based Sampling

Risk-based sampling prioritizes areas where the consequences of incorrect predictions are most severe. This strategy is guided by a risk assessment that identifies critical factors concerning compliance and patient safety. To implement this strategy, follow these steps:

• Risk Assessment: Conduct thorough risk assessments to identify high-risk areas, leveraging methodologies such as Failure Mode and Effects Analysis (FMEA).
• Focus Sampling Efforts: Allocate resources towards these high-risk areas during the sampling process.
• Documentation and Reporting: Maintain clear records of risk assessments and the rationale behind sampling decisions.

Step 4: Model Verification and Validation

Following sampling, the next crucial step in the process is model verification and validation. Verification ensures that the model acts as intended while validation confirms its effectiveness in a real-world setting. Techniques employed during this stage include:

• Performance Metrics: Establish clear metrics that reflect both the model’s efficacy and compliance with regulatory requirements.
• Cross-validation: Utilize k-fold cross-validation methods to iteratively train and assess the model’s performance.
• Independent Validation Sets: Use separate datasets to validate model predictions and minimize overfitting risks.

Step 5: Explainability and Transparency in AI/ML

Explainability is pivotal in AI/ML models, particularly in highly regulated environments like pharmaceuticals. This concept, often referred to as Explainable Artificial Intelligence (XAI), ensures that model decisions can be interpreted by stakeholders, including regulatory agencies. Key considerations for achieving explainability include:

• Documenting Model Decision Processes: Provide extensive documentation that details the model’s logic and decision-making pathways.
• Model Transparency Tools: Utilize visualization techniques to present model behavior and predictions effectively.
• Stakeholder Engagement: Involve stakeholders in the explanation process to facilitate a clearer understanding of how model predictions translate into real-world decisions.

Step 6: Drift Monitoring and Re-Validation

Once the model is deployed, it is crucial to monitor for any drift in data characteristics or performance metrics. Drift can occur due to changes in underlying data distributions or external factors affecting predictions. Monitoring and re-validation should involve the following:

• Continuous Monitoring: Set up automated systems to monitor model performance continuously against predefined metrics.
• Scheduled Re-Validation: Establish a timeline for periodic re-validation exercises, particularly after significant changes in operational processes or data sources.
• Adjustments as Needed: Be prepared to recalibrate or retrain the model based on drift analysis to maintain compliance and effectiveness.

Conclusion: Best Practices for Effective AI/ML Model Validation

In summary, the validation of AI/ML models in the pharmaceutical industry requires the integration of rigorous methodologies and adherence to regulatory expectations. By following a structured approach involving the defined intended use, ensuring data readiness, employing relevant sampling strategies, and emphasizing verification, validation, and explanation, professionals can position themselves to implement effective AI solutions.

For regulatory compliance, close attention to documentation and audit trails is essential, particularly in light of standards set forth in references like GAMP 5 and guidelines from pivotal regulatory bodies. Adhering to these standards not only mitigates risks but also reinforces the integrity and utility of AI/ML applications in the pharmaceutical landscape.